ASCO 2026 brought important momentum across colorectal cancer research: a practice-changing survival advance in targeted therapy, new questions about immunotherapy combinations, progress in blood-based testing after surgery, and emerging data on lifestyle and survivorship. This recap breaks down the most important updates by topic, helping you quickly find the research that matters most to you and your care.
Before you read: know your tumor biology: Many of the treatments below only work for specific tumor types. Your MSI/MMR status, BRAF mutation result, RAS status, and other biomarkers determine which findings apply to you. If you have not had comprehensive biomarker testing, ask your oncologist.
1. BRAF V600E: A Targeted Combination with Landmark Survival
Who this is for: Patients with BRAF V600E-mutated metastatic colorectal cancer (~8-10% of all CRC).
About 8-10% of colorectal cancers carry a BRAF V600E mutation. This mutation is often linked with more aggressive disease, but it also creates a specific target for treatment.
| BREAKWATER trial Elez et al., NEJM 2025; Kopetz et al., Nat Med 2025; ASCO 2026 Abstract LBA3503 NCT04607421 |
| Key finding: Adding encorafenib (BRAF inhibitor) and cetuximab (EGFR inhibitor) to standard chemotherapy roughly doubled median overall survival: 30.3 months vs. 15.1 months (HR 0.49; p<0.001). Response rate was 61% vs. 40%. The FDA has approved this combination as a first-line option; the mFOLFOX6 data drove the pivotal survival result. At ASCO 2026, investigators presented additional data supporting the use of a FOLFIRI chemotherapy backbone with encorafenib and cetuximab, expanding evidence for this treatment approach across commonly used first-line regimens. What it means for you: If your tumor has a BRAF V600E mutation and you have not yet been treated for metastatic disease, this combination is now a standard first-line option. Ask your care team whether FOLFOX or FOLFIRI is the right chemotherapy backbone for you. New ASCO 2026 data supports both. |
Ask your doctor:
- “Does my tumor have a BRAF V600E mutation?”
- “Am I eligible for the BREAKWATER combination as a first-line treatment?”
- “Which chemotherapy backbone, such as FOLFOX or FOLFIRI, is the better fit for my health history?”
2. MSI-H and dMMR: New Evidence on Combining Immunotherapy with Chemotherapy
Who this is for: Patients with MSI-H (microsatellite instability-high) or dMMR (deficient mismatch repair) metastatic colorectal cancer (about 4-5% of metastatic cases).
Pembrolizumab monotherapy (KEYNOTE-177, André et al., NEJM 2020) is the current FDA-approved standard for first-line MSI-H/dMMR metastatic CRC. This approach builds on earlier research demonstrating that mismatch repair-deficient tumors are uniquely sensitive to immune checkpoint blockade (Le et al., NEJM 2015). ASCO 2026 presented data examining whether adding chemotherapy and bevacizumab to immunotherapy could further improve outcomes, and whether that benefit is worth the added side effects.
| COMMIT trial Rocha Lima, Overman et al., ASCO 2026 Abstract 14 NCT02997228, NRG-GI004/SWOG-S1610 |
| Key finding: In 82 patients, the combination of mFOLFOX6 + bevacizumab + atezolizumab extended median progression-free survival to 30.0 months vs. 4.3 months with atezolizumab alone (HR 0.439; p=0.0103). Response rate was 80.6% vs. 46%. However, serious side effects were substantially higher in the combination group (34 vs. 18 Grade 3+ events), including 5 treatment-related deaths vs. 1. What it means for you: This is not a new standard of care for everyone. COMMIT used atezolizumab, a different immunotherapy agent than the FDA-approved pembrolizumab. The trial was small (102 patients) and stopped early. The data is important, especially for patients with high disease burden or aggressive biology, but the toxicity signal and lack of overall survival benefit so far mean this should be discussed carefully with your oncologist. |
Ask your doctor:
- “Is my tumor confirmed MSI-H or dMMR?”
- “Based on my disease burden, would a more intensive combination approach make sense for me?”
- “How do you weigh the COMMIT progression benefit against the safety data?”
3. MSS Colorectal Cancer: Progress for the Majority
Who this is for: The roughly 85% of colorectal cancer patients whose tumors are microsatellite stable (MSS or pMMR) and typically do not respond to standard immunotherapy.
Standard immunotherapy alone usually does not work for MSS colorectal cancer. Research in this group focuses on combinations, using targeted therapy, radiation, or chemotherapy to create conditions where immune responses may be more likely. ASCO 2026 had several trials moving this approach forward.
| SWOG S2107 Abstract 3504, Van K. Morris II |
| Key finding: A randomized phase II trial testing whether adding nivolumab (immunotherapy) to encorafenib + cetuximab (BRAF-targeted therapy) can improve outcomes in previously treated MSS BRAF V600E metastatic CRC. What it means for you: Most BRAF V600E tumors are MSS. SWOG S2107 tests the hypothesis that BRAF-targeted therapy can sensitize the tumor to immunotherapy, which is something that has not been reliably achievable in MSS CRC before. Initial ASCO 2026 results did not demonstrate a clear clinical benefit from adding nivolumab. While the study provides important biological insights, it does not currently support routine addition of nivolumab to encorafenib and cetuximab outside of a clinical trial. |
| mRCAT-III Abstract LBA3515 |
| Key finding: Testing modified short-course radiation with CAPOX chemotherapy and the PD-1 inhibitor tislelizumab vs. standard short-course radiation with CAPOX in MSS locally advanced rectal cancer. Primary endpoint: pathological complete response (no residual cancer at surgery). What it means for you: This trial tests whether targeted radiation can trigger an immune response in MSS rectal tumors, offering a different angle of attack for a population that immunotherapy alone cannot reach. |
Ask your doctor:
- “Has my tumor been fully tested, including BRAF, RAS, KRAS G12C, HER2, and NTRK?”
- “Are there active trials for MSS colorectal cancer that fit my diagnosis and treatment history?”
4. ctDNA Testing: A Blood Test That Could Guide Post-Surgery Decisions
Who this is for: Primarily patients with stage II or III colon cancer who have had surgery and are deciding on next steps.
After surgery, a key question is whether any cancer cells remain. Circulating tumor DNA (ctDNA) testing looks for fragments of cancer DNA in the bloodstream. A positive result after surgery suggests higher recurrence risk. A negative result suggests lower risk, although it does not guarantee cancer will not return.
| CIRCULATE trial Folprecht, ASCO 2026 Abstract LBA3500 NCT04089631 |
| Key finding: A European phase III randomized trial that assigned post-surgery stage II colon cancer patients to chemotherapy or observation based on their ctDNA result. This is the kind of prospective evidence needed to move ctDNA from a promising signal into a clinical standard. What it means for you: If ctDNA-guided decisions are proven to improve outcomes, the result could change how stage II colon cancer is treated. This could help move the field toward using ctDNA to identify who is most likely to need chemotherapy after surgery and who may be safely observed. |
Supporting evidence: The DYNAMIC trial (Tie et al., NEJM 2022) showed ctDNA guidance reduced chemotherapy use from 28% to 15% of stage II patients without compromising recurrence-free survival. The GALAXY study (Nakamura et al., Nature Medicine 2024) found that ctDNA positivity after surgery was associated with dramatically worse disease-free survival (HR 11.99) and overall survival (HR 9.68).
Ask your doctor:
- “Am I a candidate for ctDNA testing given my stage and surgical outcome?”
- “What would a positive or negative ctDNA result mean for my treatment plan?”
5. GLP-1 Medications: An Emerging Signal in Colorectal Cancer
Who this is for: Patients who have or may qualify for GLP-1 medications for diabetes, obesity, or cardiovascular risk. This is not a cancer treatment.
GLP-1 medications were not developed as cancer treatments, but they have generated significant attention across cancer research this year. New findings presented at both ASCO GI and ASCO 2026 raised important questions about whether these medications could influence colorectal cancer risk, progression, or survivorship outcomes. While the evidence is still early, the level of interest from researchers and clinicians makes this an area worth watching.
Three independent research teams asked whether GLP-1 receptor agonists like semaglutide, liraglutide, or dulaglutide might affect colorectal cancer risk or outcomes. None of these studies proves the medications work as cancer treatment. But taken together, they are interesting enough to study further, but they should not change cancer care on their own.
| Jones et al. ASCO GI 2026 Abstract 18 |
| Key finding: GLP-1 users were observed to have approximately one-third lower rates of colorectal cancer compared with aspirin users, with fewer serious bleeding side effects. Benefit was consistent across ages, body weights, and underlying conditions. What it means for you: If you are at elevated CRC risk and have a qualifying medical reason, discuss GLP-1 options with your care team. |
| Arya et al. ASCO GI 2026 Abstract 83 |
| Key finding: In patients already diagnosed with colon cancer who also had obesity, GLP-1 use was associated with lower mortality and fewer serious medical events. What it means for you: Relevant if you have active CRC and obesity. Worth raising with your oncologist as part of your overall health plan. |
| Orland et al. ASCO 2026 Abstract 3143, Cleveland Clinic |
| Key finding: GLP-1 use was associated with significantly lower rates of stage IV progression in stage I-III colorectal cancer: 13.4% vs. 22.2% (HR 0.69; 95% CI 0.54-0.88; p=0.003). Tumors with higher GLP-1 receptor expression also showed better overall survival. What it means for you: Early-stage patients with metabolic conditions may want to discuss these findings. Do not start a GLP-1 medication for CRC reasons based on current evidence. Randomized trials are still needed. |
Important: These are observational studies showing associations, not proof of benefit. A 2025 meta-analysis (Zhong et al., BMC Gastroenterology 2025) found mixed results depending on the comparison group. Do not start these medications based on cancer concerns alone.
Ask your doctor:
- “Do I have a medical reason, such as diabetes, obesity, or cardiovascular risk, to consider a GLP-1 medication?”
- “If I am already on one, how might it interact with my cancer treatment?”
Additional Studies Worth Knowing
These studies may matter for specific patient groups. Some results are mature, while others are early or ongoing, so the right takeaway is to ask whether any of these questions apply to your diagnosis, biomarkers, and treatment history.
| Study | Abstract | What It Tests |
| CodeBreaK 300 | Abstract 3511 | KRAS G12C mCRC: can ctDNA clearance predict early treatment response? |
| EPISODE-III | Abstract LBA3508 | Stage III colon cancer: does low-dose aspirin after surgery prevent recurrence? |
| PUMP trial | Abstract LBA3506 | Resected colorectal liver metastases: hepatic arterial infusion pump (HAIP) therapy added to standard treatment following liver surgery |
| CR-SEQUENCE | Abstract 3512 | Left-sided RAS wild-type mCRC: does starting with anti-EGFR vs. anti-VEGF therapy affect total treatment benefit? |
| CRDF-004 | Abstract 3510 | KRAS/NRAS-mutated mCRC: onvansertib + chemotherapy vs. chemotherapy alone in first line |
| Tunlametinib + vemurafenib | Abstract LBA3509 | Previously treated BRAF V600E mCRC: a different targeted combination vs. chemotherapy |
The Bottom Line
ASCO 2026 was not defined by a single headline. Instead, it highlighted meaningful progress across the colorectal cancer continuum.
Researchers reported a new standard of care for patients with BRAF V600E-mutated metastatic colorectal cancer, new questions about how best to intensify treatment for selected MSI-H/dMMR tumors, continued efforts to expand immunotherapy strategies for MSS disease, and growing evidence supporting ctDNA-guided treatment decisions after surgery, and emerging research exploring the connections between metabolic health, survivorship, and colorectal cancer outcomes.
These results do not replace a conversation with your oncologist. But they can help you ask better questions.
Know your biomarkers. Ask about clinical trials. Talk about quality of life, not just tumor response. And remember: you do not have to navigate this alone. Fight CRC is here to help you understand your options, ask informed questions, and advocate for the care you deserve.
Sign up for the Clinical Trials Newsletter
Fight CRC Resources
| Resource | Why It Connects |
| Biomarker Testing | BREAKWATER, COMMIT, MSS, ctDNA: start here to understand your tumor markers |
| ChatCRC | SWOG S2107, CIRCULATE, CRDF-004, CodeBreaK 300, and mRCAT-III may be enrolling |
| Survivorship resources | Walking, fatigue, GLP-1 metabolic health, and quality of life resources |
| About Colorectal Cancer | New to MSI-H, dMMR, MSS, BRAF, or ctDNA? Start here |
| ASCO 2026 Annual Meeting | Full abstract program for all trials in this recap |
References
1a. Elez et al. NEJM 2025. https://doi.org/10.1056/NEJMoa2501912
1b. Kopetz et al. Nature Medicine 2025. https://doi.org/10.1038/s41591-024-03443-3
1c. Kopetz et al. ASCO 2026, Abstract LBA3503. NCT04607421.
2a. Rocha Lima, Overman et al. ASCO 2026, Abstract 14. NCT02997228.
2b. André et al. NEJM 2020. https://doi.org/10.1056/NEJMoa2017699
2c. Le et al. NEJM 2015. https://doi.org/10.1056/NEJMoa1500596
3a. Morris VK II et al. ASCO 2026, Abstract 3504. SWOG S2107.
3b. Bai et al. ASCO 2026, Abstract LBA3515. mRCAT-III.
4a. Folprecht, ASCO 2026, Abstract LBA3500. NCT04089631.
4b. Tie et al. NEJM 2022. https://doi.org/10.1056/NEJMoa2200075
4c. Nakamura et al. Nature Medicine 2024. https://doi.org/10.1038/s41591-024-03254-6
5a. Jones et al. ASCO GI 2026, Abstract 18.
5b. Arya et al. ASCO GI 2026, Abstract 83.
5c. Orland et al. ASCO 2026, Abstract 3143.
6a. Pietrantonio et al. ASCO 2026, Abstract 3511. CodeBreaK 300.
6b. EPISODE-III. ASCO 2026, Abstract LBA3508.
6c. PUMP trial. ASCO 2026, Abstract LBA3506.
6d. Salazar et al. ASCO 2026, Abstract 3512. CR-SEQUENCE.
6e. Lenz et al. ASCO 2026, Abstract 3510. CRDF-004.
6f. Xu et al. ASCO 2026, Abstract LBA3509.
Medical disclaimer: This blog is for informational purposes only and does not constitute medical advice. Study results may not apply to every patient. Always consult your oncologist before making any treatment decisions. Fight CRC is a patient advocacy organization, not a medical provider.